Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Muñoz-Couselo

Showing results (1-10 of 79) with videos related to

Pageof 8
Sort By:
BMJ Case Reports|October 3, 2018
DRESS syndrome due to vemurafenib treatment: switching BRAF inhibitor to solve a big problemJavier Ros, Eva Muñoz-Couselo
Oncotargets and Therapy|December 14, 2011
Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancerEva Muñoz-Couselo, José Pérez-García, Javier Cortés
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
The effect of biology in the treatment of small breast tumorsJose Perez-Garcia, Eva Muñoz-Couselo, Javier Cortes
Oncotargets and Therapy|June 17, 2021
Current Perspectives and Novel Strategies of <i>NRAS</i>-Mutant MelanomaAlejandro Garcia-Alvarez, Carolina Ortiz, Eva Muñoz-Couselo
Seminars in Oncology|December 3, 2014
Therapeutic antibodies in breast cancerJosé Pérez-Garcia, Eva Muñoz-Couselo, Javier Cortés, et al.
BMJ Case Reports|January 29, 2021
Mediastinal FDG-positive lymph nodes simulating melanoma progression: drug-induced sarcoidosis like/lymphadenopathy related to ipilimumabCarlos González-Cruz, Domingo Bodet, Eva Muñoz-Couselo, et al.
Melanoma Research|July 27, 2019
The role of ipilimumab after anti-PD-1 treatment: two case reports and a literature reviewJavier Ros-Montañá, Nadia Saoudi-Gonzalez, Carolina Ortiz-Velez, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 8, 2026
Subcutaneous immunotherapy as a catalyst for decentralized, oncologist-led cancer care: a mixed-methods analysisEva Muñoz-Couselo, Julia Lostes, Giulia Pretelli, et al.
Expert Review of Anticancer Therapy|June 18, 2010
Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancerJosep M Del Campo, Eva Muñoz-Couselo, Isabella Diaz de Corcuera, et al.
Oncotargets and Therapy|September 2, 2017
<i>NRAS</i>-mutant melanoma: current challenges and future prospectEva Muñoz-Couselo, Ester Zamora Adelantado, Carolina Ortiz, et al.
Pageof 8

Showing results (1-10 of 79) with videos related to

Sort By:
Pageof 8
BMJ Case Reports|October 3, 2018
DRESS syndrome due to vemurafenib treatment: switching BRAF inhibitor to solve a big problemJavier Ros, Eva Muñoz-Couselo
Oncotargets and Therapy|December 14, 2011
Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancerEva Muñoz-Couselo, José Pérez-García, Javier Cortés
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
The effect of biology in the treatment of small breast tumorsJose Perez-Garcia, Eva Muñoz-Couselo, Javier Cortes
Oncotargets and Therapy|June 17, 2021
Current Perspectives and Novel Strategies of <i>NRAS</i>-Mutant MelanomaAlejandro Garcia-Alvarez, Carolina Ortiz, Eva Muñoz-Couselo
Seminars in Oncology|December 3, 2014
Therapeutic antibodies in breast cancerJosé Pérez-Garcia, Eva Muñoz-Couselo, Javier Cortés, et al.
BMJ Case Reports|January 29, 2021
Mediastinal FDG-positive lymph nodes simulating melanoma progression: drug-induced sarcoidosis like/lymphadenopathy related to ipilimumabCarlos González-Cruz, Domingo Bodet, Eva Muñoz-Couselo, et al.
Melanoma Research|July 27, 2019
The role of ipilimumab after anti-PD-1 treatment: two case reports and a literature reviewJavier Ros-Montañá, Nadia Saoudi-Gonzalez, Carolina Ortiz-Velez, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 8, 2026
Subcutaneous immunotherapy as a catalyst for decentralized, oncologist-led cancer care: a mixed-methods analysisEva Muñoz-Couselo, Julia Lostes, Giulia Pretelli, et al.
Expert Review of Anticancer Therapy|June 18, 2010
Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancerJosep M Del Campo, Eva Muñoz-Couselo, Isabella Diaz de Corcuera, et al.
Oncotargets and Therapy|September 2, 2017
<i>NRAS</i>-mutant melanoma: current challenges and future prospectEva Muñoz-Couselo, Ester Zamora Adelantado, Carolina Ortiz, et al.
Pageof 8